## FISH upgrades for improved virtual analysis, 5/14

May 2014—Clarient Diagnostic Service, a GE Healthcare company, upgraded its fluorescence in situ hybridization technologies to improve virtual analysis of test results for leukemia, lymphoma, myelodysplastic syndrome, and myeloma. The PathSite Virtual HemeFISH (VHF) service is part of the upgrades and an integrated component of the Web-based case management portal. PathSite VHF will help pathologists interpret, diagnose, and report on suspected blood cancers and disorders; manage cases remotely; streamline workflow with tools to review, classify, filter, and approve each cell; and use a comprehensive reporting tool to create professional, user-branded reports.

GE Healthcare, 609-514-6046